REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Protocols
9

TB-500 Dosing Guide Discussion

Echo Hawkins·2 months ago
Wanted to start a discussion about TB-500 dosing approaches. I have been compiling information from various sources and thought it would be useful to share and get community input. From what I have gathered, there seem to be two main schools of thought on TB-500 dosing. The first is a lower dose, higher frequency approach, which aims for steady-state levels. The second is a higher dose, lower frequency approach that creates more of a pulsatile pattern. I have been running the higher frequency approach for the past 6 weeks. My reasoning is that maintaining more consistent levels should produce more stable results with fewer peaks and troughs. So far this seems to be working well. One thing I want to emphasize is the importance of proper reconstitution technique. I use bacteriostatic water, inject slowly along the vial wall, and swirl gently rather than shaking. Storage is refrigerated at 2-8C after reconstitution. What approach is everyone else taking? I am curious whether others have found one method superior to the other.

Comments (4)

Taylor BishopDEMO·2 months ago

I ran TB-500 at a slightly higher dose than what you used and found the results were actually about the same. This lines up with the dose-response data suggesting there is a ceiling effect. Higher dose just meant more injection site irritation without additional benefit. Your approach seems well-calibrated.

5
Blue ArmstrongDEMO·2 months ago

The sleep improvement you mention with TB-500 has been the most universally reported benefit I see across different users. It seems like regardless of primary goals, almost everyone reports better sleep quality. I wonder if this is a direct effect or downstream from other physiological changes.

6
Spencer DawsonDEMO·2 months ago

Thanks for the detailed protocol breakdown. I am starting TB-500 next week and this is exactly the kind of practical information I was looking for. The reconstitution tips especially — I have seen conflicting advice elsewhere about water temperature and injection speed. Your approach sounds well-reasoned.

2
Bailey ArnoldDEMO·2 months ago

Been following this thread with interest. My TB-500 experience was similar in most ways, though I found the recovery benefits took a bit longer to kick in for me — closer to week 5-6 rather than 3-4. Individual variation is real and I think people need to be patient before concluding something is or is not working.

3

Sign in to comment.